Ann: Market Update, page-26

@prowiz

Aegros is progressing nicely

In my opinion there's more than 99% CSL buy into Aegros before IPO

CSL stand to lose the most if Aegros succeeds as a plasma competitor or benefit the most from acquiring Aegros prior to IPO

Aegros & CSL are both presenting at upcoming July Protein conference in Brisbane

to think CSL isn't very interested in Aegros as a significant competitor or shrewd acquisition seems far fetched

It's possible that international fractionators are willing to pay massive premium to acquire Aegros - CSL can potentially dominate global plasma markets if it acquires Aegros - or waste an opportunity & risk the rise of Aegros plasma technology

interesting times ahead & can't see CSL allowing Aegros to fall into foreign hands or influence